Gamble JM, et al. - This cohort study was designed to determine the relationship between dipeptidyl peptidase-4 (DPP-4) inhibitors and common osteoporotic “fragility fractures” (upper extremity, hip, spine). Compared with sulfonylureas (SUs) or insulin, DPP-4 inhibitors were not associated with an increased risk of fragility fractures. However, DPP-4 inhibitors were correlated with a significantly lower fracture risk when compared with thiazolidinediones.